SEARCH

SEARCH BY CITATION

References

  • 1
    Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am. 1997;26:125144.
  • 2
    Yancy CW. Heart failure in African Americans: a cardiovascular enigma. J Card Fail. 2000;6:183186.
  • 3
    Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol. 1993;22(Suppl A):(14A19A.
  • 4
    Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609616.
  • 5
    Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:13511357.
  • 6
    Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:14111420.
  • 7
    Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821828.
  • 8
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:14291435.
  • 9
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:16701676.
  • 10
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669677.
  • 11
    SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685691.
  • 12
    SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293302.
  • 13
    Ofili E, Flack J, Gibbons G. Race and responsiveness to drugs for heart failure [letter]. N Engl J Med. 2001;345:767.
  • 14
    Weir MR, Saunders E, for the Trandolopril Multicenter Study Group. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African Americans. J Human Hypertens. 1998;12:189194.
  • 15
    Saunders E, Weir MR, Kong W, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:17071713.
  • 16
    Dries DL, Strong MH, Cooper RS, et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40:311317.
  • 17
    American College of Clinical Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Available at: http:www.acc.org. Accessed September 5, 2002.
  • 18
    Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail. 1999;5:357382.
  • 19
    GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:18571863.
  • 20
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:14561462.
  • 21
    Maschio G, Alberti D, Janin G, et al. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939945.
  • 22
    Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA. 2001;285:27192728.
  • 23
    American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.
  • 24
    Broderick J, Brott T, Kothari R, et al. The greater Cincinnati/Northern Kentucky stroke study. Stroke. 1998;29: 415421.
  • 25
    Strauss SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA. 2002;288: 13881395.
  • 26
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment of older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:32553264.
  • 27
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertension patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 28
    Sica DA. ACE inhibitors and stroke: new considerations. J Clin Hypertens. 2000;4:126129, 133.
  • 29
    Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. Br J Med. 2002; 324:699702.
  • 30
    PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:10331041.
  • 31
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145153.
  • 32
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355: 253259.
  • 33
    Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332:8085.
  • 34
    Gruppo Italiano per lo Studio della Sopravvivenz nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate single and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:11151122.
  • 35
    Fourth International Study of Infarct Survival Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669685.
  • 36
    Latini R, Maggioni AP, Flather M, et al. ACE-inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 1995;92:31323137.
  • 37
    Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. Available at: http:www.americanheart.org. Accessed September 5, 2002.